{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-069818","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.430442+00:00","generated_at":"2026-05-21T14:56:56.177499+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Atossa Q1 cash $65.1M; pivots (Z)-endoxifen to metastatic breast cancer","bullets":["Ended Q1 2025 with $65.1M cash, no debt; no revenue reported.","Strategic shift to metastatic breast cancer as lead indication for (Z)-endoxifen.","Added 3 new US patents, expanding IP portfolio to over 200 claims related to (Z)-endoxifen.","Operating expenses $7.4M (up $0.4M YoY) with R&D $4.2M, G&A $3.3M.","Interest income $0.7M, down from $1.1M due to lower money market balance."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-069818","json":"https://secwatch.observer/filing/0000950170-25-069818.json","markdown":"https://secwatch.observer/filing/0000950170-25-069818.md","text":"https://secwatch.observer/filing/0000950170-25-069818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025069818/0000950170-25-069818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025069818/atos-20250513.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T14:56:56.177499+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}